BIOT

424B3 - Relativity Holdings Inc. (0002072188) (Filer)

EFFECT - Relativity Holdings Inc. (0002072188) (Filer)

POS AM - Relativity Holdings Inc. (0002072188) (Filer)

F-4/A - Relativity Holdings Inc. (0002072188) (Filer)

F-4/A - Relativity Holdings Inc. (0002072188) (Filer)

SC 13G/A - Biotech Acquisition Co (0001825413) (Subject)

15-12G - Biotech Acquisition Co (0001825413) (Filer)

SC 13G/A - Biotech Acquisition Co (0001825413) (Subject)

SC 13G - Biotech Acquisition Co (0001825413) (Subject)

SC 13G/A - Biotech Acquisition Co (0001825413) (Subject)

SC 13G/A - Biotech Acquisition Co (0001825413) (Subject)

25-NSE - Biotech Acquisition Co (0001825413) (Subject)

8-K - Biotech Acquisition Co (0001825413) (Filer)

Biotech Acquisition Company (the "Company") (NASDAQ:BIOT), announced today that it will not implement the extension of the time period the Company has to complete an initial business combination as approved by its shareholders at an extraordinary general meeting of shareholders held on January 19, 2023 as a result of the investor being unable to deposit the requisite funds into the Company's trust account ("Trust Account") for the extension. As a result, the Company will dissolve and liquidate in accordance with the provisions of its Amended and Restated Memorandum and Articles of Association, as amended (the "Charter") and will redeem all of the outstanding ordinary shares that were include

New York, New York, Feb. 01, 2023 (GLOBE NEWSWIRE) --  Biotech Acquisition Company (the "Company") (NASDAQ:BIOT), announced today that it will not implement the extension of the time period the Company has to complete an initial business combination as approved by its shareholders at an extraordinary general meeting of shareholders held on January 19, 2023 as a result of the investor being unable to deposit the requisite funds into the Company's trust account ("Trust Account") for the extension. As a result, the Company will dissolve and liquidate in accordance with the provisions of its Amended and Restated Memorandum and Articles of Association, as amended (the "Charter") and will redeem

SC 13G - Biotech Acquisition Co (0001825413) (Subject)

8-K - Biotech Acquisition Co (0001825413) (Filer)

SC 13G - Biotech Acquisition Co (0001825413) (Subject)

8-K - Biotech Acquisition Co (0001825413) (Filer)

 Biotech Acquisition Company (NASDAQ:BIOT) (the "Company"), a publicly traded special purpose acquisition company, today announced that in connection with a proposed extension (the "Extension") of the time period the Company has to complete an initial business combination, as described in the Proxy Statement (as defined below), IREEM LLC, which has entered into an agreement to acquire the current sponsor's interest in the Company (as described in the Proxy Statement), will deposit into the Company's trust account (the "Trust Account") for each additional month the lesser of (i) an aggregate of $457,500 or (ii) $0.055 per share that remains outstanding and is not redeemed in connection with t

NEW YORK, Jan. 4, 2023 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ:BIOT) (the "Company"), a publicly traded special purpose acquisition company, today announced that in connection with a proposed extension (the "Extension") of the time period the Company has to complete an initial business combination, as described in the Proxy Statement (as defined below), IREEM LLC, which has entered into an agreement to acquire the current sponsor's interest in the Company (as described in the Proxy Statement), will deposit into the Company's trust account (the "Trust Account") for each additional month the lesser of (i) an aggregate of $457,500 or (ii) $0.055 per share that remains outstanding an

DEF 14A - Biotech Acquisition Co (0001825413) (Filer)

8-K - Biotech Acquisition Co (0001825413) (Filer)

PRE 14A - Biotech Acquisition Co (0001825413) (Filer)

NT 10-Q - Biotech Acquisition Co (0001825413) (Filer)